A Rash of Developments in Chronic Spontaneous Urticaria Treatment and Management - Baseline Assessment

Answer the following questions to assess your knowledge of the diagnosis and treatment of patients with chronic spontaneous urticaria.

Jonathan A. Bernstein, MD

Partner, Bernstein Allergy Group, Inc.
Professor of Medicine, Division of Allergy & Immunology
University of Cincinnati

Dr. Bernstein is an allergy specialist with over 35 years of experience treating patients with asthma, urticaria, angioedema, atopic and contact dermatitis, and women’s allergic health issues, such as chronic candida vulvovaginitis. Over his career, he has published over 275 peer-reviewed articles in allergy and clinical immunology and has been ranked by US News and World Report as being in the top 1% of doctors in his field. Dr. Bernstein, in previous years, additionally served as the president of the Academy of Allergy, Asthma & Immunology – a nationwide organization with a membership of over 7,000 allergy clinicians.

Brian S. Kim, MD

Vice Chair of Research, Department of Dermatology
Icahn School of Medicine, Mount Sinai

Dr. Kim is a leading researcher worldwide in the study of patients with dermatological conditions involving itch. His research endeavors to elucidate the mechanisms that underlie neuroimmune interactions at the skin barrier surface. Over the course of his career, Dr. Kim has received the American Skin Association Research Achievement Award in Discovery (2020) and the American Dermatological Association Young Leadership Award (2019) and has published in internationally esteemed journals including the European Respiratory Journal, JAMA Dermatology, Cell, and the New England Journal of Medicine.
1.
Identify and address the diagnostic challenges leading to treatment delays for patients with CSU
2.
Describe the underlying pathophysiology of CSU, with a focus on type I and type II autoimmune mechanisms
3.
Discuss the mechanism of action, efficacy, and safety profiles of novel treatments for CSU, namely Bruton’s tyrosine kinase (BTK) inhibitors
4.
Explore strategies to improve coordination among specialists and supporting advanced practice providers to ensure appropriate de-escalation of treatment